JMP reiterates ViroPharma at market outperform

ViroPharma Inc. was reiterated by JMP Securities analyst Adam Cutler at market outperform. The company's Vancocin sales of $29.2 million fell short of JMP's estimate of $40.4 million. Earnings per share of $0.12 also missed the analyst's mark of $0.20 and the Street consensus of $0.21. ViroPharma maintained its 2006 guidance of $160 million to $170 million for Vancocin sales and reduced guidance for operating income growth to 10% to 20% from 10% to 25%. Shares of the Exton, Pa., pharmaceutical company were down 62 cents, or 6.25%, at $9.30 on volume of 3,298,314 shares versus the three-month running average of 4,281,630 shares. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.